It’s been two years since President Trump signed the “Right-to-Try” Drug Bill into law. The legislation gave terminally ill patients access to experimental medical treatments yet to be approved by the Food and Drug Administration (FDA).
Despite the opportunities offered by the new law, some patients are still struggling to get access to experimental drugs that are awaiting approval from the FDA that could improve their conditions.
Mike Moutsoulas, a 43-year-old father of three children between the ages of 4 and 7, was diagnosed with amyotrophic lateral sclerosis (ALS), the neurodegenerative disease commonly known as Lou Gehrig’s disease in November 2019. He and his sister, Stephenie, 44, who was also diagnosed with ALS back in December 2018, have been fighting to make more promising treatments for the disease available to ALS patients like themselves that loopholes in the Right-to-Try Drug Bill prevent them from having access to.
Mike and Stephenie have a form of the disease that is genetic. Their biological mother and her sister both died of ALS. The disease has a 100 percent fatality rate.
There are currently two bills that would open up access to various treatments that could offer hope to the Moutsoulases and other ALS patients: the Promising Pathway Act, and the Accelerated Access to Critical Therapies (ACT) for ALS Act. While these bills would provide expedited access to new treatments and increase funding for ALS, it could take a year for these bills to go through the legislative process and become law. Moutsoulas and other ALS patients would benefit greatly if existing treatments stuck in clinical trials were accessible to them.
Moutsoulas is a Navy veteran and a longtime active member of his local community. In 2005, he ran and won a four-year term on the School Committee of his hometown, and later served on the city’s Board of Registrars.
In May, Moutsoulas participated in the #ShaveALSChallenge, which, similar to ALS Ice Bucket Challenge, encouraged people to shave their heads to raise awareness about promising ALS treatments stuck in clinical trials:
Moutsoulas and 55 other ALS patients and their families also traveled to Washington, D.C., to demonstrate in front of the White House, calling for greater access to experimental treatments. Moutsoulas also wrote a letter to President Trump (which he provided to PJ Media) noting that during the COVID-19 pandemic the FDA was able fast-track experimental drugs through the approval process, and urged him to sign an executive order that could provide similar hope for people suffering from ALS.
Here is a portion of Moutsoulas’s letter:
Currently, there are no approved treatments or a cure for ALS. There is a safe and promising treatment called NurOwn that has been in clinical trials for a DECADE. It has shown in the clinical trials to have slowed, stopped, and even reversed ALS in some patients. It’s not a cure, but could be a long-term treatment option, much how we treat Diabetes and other chronic illnesses. There has never been anything more promising in the 150 year history of ALS than NurOwn. Sadly, we only have 2 FDA approved drugs for ALS, which are said to extend a patient’s life by a few months if taken early enough.
The recent urgency in which the FDA is pushing experimental Covid-19 drugs through their process, gives ALS patients hope that a similar pathway can be created to allow patients the right to try NurOwn and other promising treatments, such as T-REGS, CuATSM, AMX0035, Prosetin, Mastinib, and others. ALS is 100% fatal. Why can’t the same urgency apply for ALS?
I write to you Mr. President to ask that you please sign an Executive Order to allow an immediate pathway to NurOwn, and other promising ALS treatments. By doing this, you will make a terminal disease in ALS a treatable one. The Moutsoulas Family would be forever grateful. Thank you for your time and consideration.
President Trump would be well within his authority to sign an executive order to expand the availability of these potential long-term treatments for ALS in the spirit of the Right-to-Try law. Waiting for a dysfunctional U.S. Congress to pass legislation isn’t good enough for those afflicted with ALS whose only roadblock to potentially life-extending drugs is government bureaucracy.
Disclaimer: Mike Moutsoulas is a personal acquaintance of the author of this article.